BidaskClub cut shares of Exelixis (NASDAQ:EXEL) from a hold rating to a sell rating in a report published on Tuesday morning, BidAskClub reports.

A number of other research analysts also recently issued reports on EXEL. Oppenheimer set a $13.00 price objective on shares of Alpine Immune Sciences and gave the stock a buy rating in a research report on Tuesday, March 19th. ValuEngine downgraded shares of Intersect ENT from a buy rating to a hold rating in a research report on Monday. Morgan Stanley boosted their target price on shares of Zynga and gave the stock an overweight rating in a research report on Thursday, May 2nd. Zacks Investment Research downgraded shares of Great Portland Estates from a hold rating to a sell rating in a research report on Tuesday, April 16th. Finally, Cowen raised shares of Twitter from an underperform rating to a market perform rating in a research report on Tuesday, April 23rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $28.88.

Shares of Exelixis stock opened at $20.89 on Tuesday. The stock has a 50 day moving average price of $20.56. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.48 and a current ratio of 7.56. Exelixis has a 52-week low of $13.42 and a 52-week high of $25.31. The stock has a market cap of $6.30 billion, a P/E ratio of 14.61, a P/E/G ratio of 0.49 and a beta of 1.93.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.24. Exelixis had a net margin of 75.97% and a return on equity of 37.21%. The firm had revenue of $215.49 million for the quarter, compared to the consensus estimate of $206.06 million. During the same quarter in the previous year, the firm earned $0.40 EPS. The company’s quarterly revenue was up .8% compared to the same quarter last year. As a group, equities research analysts expect that Exelixis will post 0.92 earnings per share for the current fiscal year.

In other news, EVP Peter Lamb sold 217,404 shares of the company’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $20.59, for a total value of $4,476,348.36. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Michael Morrissey sold 40,000 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $20.75, for a total transaction of $830,000.00. The disclosure for this sale can be found here. Insiders sold a total of 569,982 shares of company stock worth $11,691,192 over the last ninety days. Insiders own 4.50% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Cutler Capital Management LLC raised its stake in shares of Exelixis by 10.0% during the fourth quarter. Cutler Capital Management LLC now owns 11,000 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 1,000 shares during the last quarter. LPL Financial LLC raised its stake in shares of Exelixis by 36.3% during the fourth quarter. LPL Financial LLC now owns 15,455 shares of the biotechnology company’s stock valued at $304,000 after acquiring an additional 4,116 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Exelixis by 20.7% during the fourth quarter. Bank of New York Mellon Corp now owns 3,743,157 shares of the biotechnology company’s stock valued at $73,628,000 after acquiring an additional 643,023 shares during the last quarter. Advisor Group Inc. raised its stake in Exelixis by 25.4% in the fourth quarter. Advisor Group Inc. now owns 7,791 shares of the biotechnology company’s stock worth $153,000 after buying an additional 1,576 shares in the last quarter. Finally, State of Tennessee Treasury Department raised its stake in Exelixis by 233.7% in the fourth quarter. State of Tennessee Treasury Department now owns 102,028 shares of the biotechnology company’s stock worth $2,007,000 after buying an additional 71,452 shares in the last quarter. 78.21% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Company Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: What is the CBOE Russell 2000® Volatility Index?

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.